Document is current

Article History

Received: 6 October 2025

Accepted: 23 January 2026

First Online: 3 March 2026

Declarations

:

: William B. Nowell, Oren Levy, and Nick Patel are employees of Regeneron Pharmaceuticals, Inc., and hold stock in Regeneron Pharmaceuticals, Inc. Nadine McGale, Sarah Wilding, and Phoebe Heinrich are employees of Modus Outcomes, a THREAD company. Jinsy A. Andrews has served as a consultant for AL-S Pharma AG (data safety monitoring board [DSMB]), Amylyx Pharmaceuticals, Biogen, Cytokinetics, Neurosense Therapeutics, Akava, QurAlis (DSMB), Regeneron Pharmaceuticals, Inc., and Sanofi (DSMB); and has received research funding to their institution from The ALS Association, Biogen, Cytokinetics, Corcept Therapeutics, ALS Platform Trial (Biohaven, Clene Inc., Ra Pharmaceuticals, Prilenia Therapeutics, Calico, Denali Therapeutics, and The Montreal General Hospital Foundation), and National Institute of Health/National Institute of Neurological Disorders and Stroke. Diana Rofail is a full-time employee of Regeneron Pharmaceuticals, Inc., and holds stock in Regeneron Pharmaceuticals, Inc., and Roche.

: The Western-Copernicus Group Institutional Review Board’s Affairs Department reviewed the study protocol under the Common Rule and applicable guidance, and approved a request for a waiver of authorization for the use and disclosure of protected health information. Participants were paid a fee in line with fair market value to cover their time taken to participate in the study. This study is reported in accordance with the Consolidated Criteria for Reporting Qualitative Research guidelines [ ].